Anti-Fibrotic Drug Recruiting Patients Across the Country for Phase 2 Clinical Trial

Researchers are currently recruiting patients for the PROMOTE study, a phase 2 trial of PRM-151 in subjects with primary myelofibrosis, post-polycythemia vera, or post-essential thrombocythemia. PRM-151 is a recombinant form of pentraxin-2 (PTX-2), a protein that circulates in the blood stream that helps to regulate tissue repair.

 The MPN Research Foundation

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.